vs
EXELIXIS, INC.（EXEL）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是UiPath, Inc.的1.5倍（$598.7M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs 40.8%，领先7.5%），UiPath, Inc.同比增速更快（15.9% vs 5.6%），EXELIXIS, INC.自由现金流更多（$332.4M vs $25.1M），过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs 0.7%）
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
EXEL vs PATH — 直观对比
营收规模更大
EXEL
是对方的1.5倍
$411.1M
营收增速更快
PATH
高出10.3%
5.6%
净利率更高
PATH
高出7.5%
40.8%
自由现金流更多
EXEL
多$307.3M
$25.1M
两年增速更快
EXEL
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $598.7M | $411.1M |
| 净利润 | $244.5M | $198.8M |
| 毛利率 | 95.6% | 83.3% |
| 营业利润率 | 39.3% | 3.2% |
| 净利率 | 40.8% | 48.4% |
| 营收同比 | 5.6% | 15.9% |
| 净利润同比 | 74.8% | 1966.2% |
| 每股收益（稀释后） | $0.89 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXELPATH
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $411.1M | ||
| Q3 25 | $568.3M | $361.7M | ||
| Q2 25 | $555.4M | $356.6M | ||
| Q1 25 | $566.8M | $423.6M | ||
| Q4 24 | — | $354.7M | ||
| Q3 24 | $539.5M | $316.3M | ||
| Q2 24 | $637.2M | $335.1M |
净利润EXELPATH
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $198.8M | ||
| Q3 25 | $184.8M | $1.6M | ||
| Q2 25 | $159.6M | $-22.6M | ||
| Q1 25 | $139.9M | $51.8M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | $118.0M | $-86.1M | ||
| Q2 24 | $226.1M | $-28.7M |
毛利率EXELPATH
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 83.3% | ||
| Q3 25 | 96.6% | 82.2% | ||
| Q2 25 | 96.5% | 82.1% | ||
| Q1 25 | 96.5% | 84.8% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | 96.8% | 80.0% | ||
| Q2 24 | 97.2% | 83.5% |
营业利润率EXELPATH
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 3.2% | ||
| Q3 25 | 37.6% | -5.6% | ||
| Q2 25 | 33.6% | -4.6% | ||
| Q1 25 | 28.8% | 7.9% | ||
| Q4 24 | — | -12.2% | ||
| Q3 24 | 25.2% | -32.7% | ||
| Q2 24 | 43.3% | -14.8% |
净利率EXELPATH
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 48.4% | ||
| Q3 25 | 32.5% | 0.4% | ||
| Q2 25 | 28.7% | -6.3% | ||
| Q1 25 | 24.7% | 12.2% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | 21.9% | -27.2% | ||
| Q2 24 | 35.5% | -8.6% |
每股收益（稀释后）EXELPATH
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.37 | ||
| Q3 25 | $0.65 | $0.00 | ||
| Q2 25 | $0.55 | $-0.04 | ||
| Q1 25 | $0.47 | $0.09 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.40 | $-0.15 | ||
| Q2 24 | $0.77 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $1.9B |
| 总资产 | $2.8B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXELPATH
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $1.4B | ||
| Q3 25 | $791.1M | $1.4B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.0B | $1.9B |
股东权益EXELPATH
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.9B | ||
| Q3 25 | $2.0B | $1.7B | ||
| Q2 25 | $2.1B | $1.7B | ||
| Q1 25 | $2.2B | $1.8B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $2.3B | $1.8B | ||
| Q2 24 | $2.1B | $2.0B |
总资产EXELPATH
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.9B | ||
| Q3 25 | $2.7B | $2.6B | ||
| Q2 25 | $2.8B | $2.6B | ||
| Q1 25 | $2.9B | $2.9B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $3.0B | $2.7B | ||
| Q2 24 | $2.8B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $333.5M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $332.4M | $25.1M |
| 自由现金流率自由现金流/营收 | 55.5% | 6.1% |
| 资本支出强度资本支出/营收 | 0.2% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.36× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $875.8M | — |
8季度趋势，按日历期对齐
经营现金流EXELPATH
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $28.3M | ||
| Q3 25 | $49.0M | $41.6M | ||
| Q2 25 | $211.4M | $119.0M | ||
| Q1 25 | $240.3M | $146.1M | ||
| Q4 24 | — | $28.1M | ||
| Q3 24 | $271.3M | $46.4M | ||
| Q2 24 | $119.5M | $100.0M |
自由现金流EXELPATH
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $25.1M | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | $106.2M | ||
| Q1 25 | $236.3M | $138.7M | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | $263.1M | $45.0M | ||
| Q2 24 | $113.0M | $98.8M |
自由现金流率EXELPATH
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 6.1% | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | 29.8% | ||
| Q1 25 | 41.7% | 32.7% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | 48.8% | 14.2% | ||
| Q2 24 | 17.7% | 29.5% |
资本支出强度EXELPATH
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.8% | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.5% | 3.6% | ||
| Q1 25 | 0.7% | 1.7% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 1.5% | 0.4% | ||
| Q2 24 | 1.0% | 0.4% |
现金转化率EXELPATH
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 0.14× | ||
| Q3 25 | 0.27× | 26.25× | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
